Breath tests to phenotype drug disposition in oncology

Clinical Pharmacokinetics

Volumn 52, Issue 11, 2013, Pages 919-926

  Opdam, Frans L ^a   Modak, Anil S ^b   Gelderblom, Hans ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN C 13; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; ENDOXIFEN; ERYTHROMYCIN; FLUOROPYRIMIDINE; FLUOROURACIL; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IFOSFAMIDE; IMATINIB; IRINOTECAN; MIDAZOLAM; NAVELBINE; PACLITAXEL; TAMOXIFEN; TEGAFUR; TRACER; UNCLASSIFIED DRUG; URACIL C 13;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST METASTASIS; BREATH ANALYSIS; CANCER PATIENT; COLORECTAL CANCER; DIAGNOSTIC TEST; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; LUNG NON SMALL CELL CANCER; NON INVASIVE PROCEDURE; PHENOTYPE; PRIORITY JOURNAL; SARCOMA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTINEOPLASTIC AGENTS; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DIHYDROURACIL DEHYDROGENASE (NADP); ERYTHROMYCIN; HUMANS; NEOPLASMS; PHENOTYPE; URACIL;

EID: 84886791467     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0099-9     Document Type: Article

References (64)

1. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci USA. 1971;68:2374-6.
2. Afolabi P, Wright M, Wootton SA, Jackson AA. Clinical utility of C-13-liver-function breath tests for assessment of hepatic function. Dig Dis Sci. 2013;58:33-41.
3. Minh TDC, Blake DR, Galassetti PR. The clinical potential of exhaled breath analysis for diabetes mellitus. Diabetes Res Clin Pract. 2012;97:195-205.
4. Paschke KM, Mashir A, Dweik RA. Clinical applications of breath testing. F1000 Med Rep. 2010;2:56.
5. Chapman EA, Thomas PS, Yates DH. Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res. 2010;4:034001.
6. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84:287-94.
7. Opdam FL, Gelderblom H, Guchelaar HJ. Phenotyping drug disposition in oncology. Cancer Treat Rev. 2012;38:715-25.
8. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther. 2007;81:270-83.
9. de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol. 2011;29:3240-6.
10. Perera V, Gross AS, McLachlan AJ. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed Chromatogr. 2010;24:1136-44.
11. Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 micron particle size column. J Chromatogr A. 2008;1215:107-15.
12. Modak A. Diagnostic breath tests in personalized medicine. Expert Rev Mol Diagn. 2008;8:563-4.
13. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [(13)C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol. 2008;48:1041-51.
14. Modak AS. Stable isotope breath tests in clinical medicine: a review. J Breath Res. 2007;1:014003.
15. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989;83:688-97.
16. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4:171-84.
17. Schmidt LE, Olsen AK, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. Clin Pharmacol Ther. 2001;70:446-54.
18. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther. 1992;51:229-38.
19. Kurnik D, Wood AJJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther. 2006;80:228-34.
20. Lan LB, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol. 2000;58:863-9.
21. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther. 2008;84:704-9.
22. Franke RM, Baker SD, Schuetz EG, Sparreboom A. ABCC2 polymorphism as a determinant of the erythromycin breath test. Clin Pharmacol Ther. 2009;85:S67.
23. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990;38:207-13.
24. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187-216.
25. Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res. 2000;6:3480-5.
26. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology. 1994;20:309-16.
27. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther. 1992;52:471-8.
28. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther. 1990;48:120-9.
29. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther. 1995;57:16-24.
30. Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther. 2004;76:341-9.
31. Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther. 1999;66:224-31.
32. Krivoruk Y, Kinirons MT, Wood AJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther. 1994;56:608-14.
33. Kinirons MT, Krivoruk Y, Wilkinson GR, Wood AJ. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. Br J Clin Pharmacol. 1999;47:223-5.
34. Gharaibeh MN, Gillen LP, Osborne B, Schwartz JI, Waldman SA. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers. J Clin Pharmacol. 1998;38:492-5.
35. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6:1255-8.
36. Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res. 2006;12:6100-5.
37. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EYL, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol. 2004;57:44-53.
38. Michael M, Cullinane C, Hatzimihalis A, O'Kane C, Milner A, Booth R, et al. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemother Pharmacol. 2012;69:125-35.
39. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther. 1992;52:265-73.
40. Hooker AC, Ten Tije AJ, Carducci MA, Weber J, Garrett-Mayer E, Gelderblom H, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P450 3A activity measurements. Clin Pharmacol Ther. 2008;84:111-8.
41. Sparreboom A, Huizing MT, Boesenwillem JJB, Nooijen WJ, Vantellingen O, Beijnen JH. Isolation, purification, and biological-activity of monohydroxylated and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol. 1995;36:299-304.
42. Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, et al. Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol. 2012;74:197-200.
43. Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 2006;58:129-35.
44. Chugh R, Wagner T, Griffith KA, Taylor JM, Thomas DG, Worden FP, et al. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer. 2007;109:2315-22.
45. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004;96:1585-92.
46. Schellens JHM. Capecitabine. Oncologist. 2007;12:152-5.
47. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-6.
48. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12:5491-5.
49. Deenen MJ, Tol J, Burylo AM, Doodeman VD, De Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17:3455-68.
50. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-902.
51. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res. 2004;10:2652-8.
52. 2 and plasma [2-13C]dihydrouracil. Clin Cancer Res. 2006;12:549-55.
53. Ishii Y, Suzuki S, Takahashi Y, Takayama T, Asai S. Can the 2-C-13-uracil breath test be used to predict the effect of the antitumor drug S-1? Cancer Chemother Pharmacol. 2010;66:333-43.
54. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:692-706.
55. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997;57:3402-6.
56. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718-25.
57. Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, et al. The use of the (13)C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol. 2013;71(3):593-601.
58. Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, et al. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther. 2009;329:297-305.
59. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J. 2005;5:365-73.
60. Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol. 2010;70:844-53.
61. US Food and Drug Administration. Drugs: genomics. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/default.htm. Accessed 20 Apr 2012.
62. de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44:147-73.
63. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85:155-63.
64. Breath test for women receiving tamoxifen in the prevention or treatment of breast cancer [ClinicalTrials.gov identifier NCT00873366]. http://www.clinicaltrials.gov/ct2/show/NCT00873366?term=breath+test&rank=3. Accessed 20 May 2013.